Coastal Infusion Administers Entyvio®

Entyvio (burosumab-twza) is used to treat X-linked hypophosphatemia (XLH). XLH is a rare genetic disorder where the kidneys excrete too much phosphate into the urine, leading to low levels of phosphate in the blood. This results in impaired bone mineralization and can cause skeletal abnormalities. Patients with X-linked hypophosphatasemia or tumor-induced osteomalacia have abnormally high levels of FGF23, which causes the kidneys to stop returning phosphate into the bloodstream.

Entyvio is a monoclonal antibody designed to recognize and attach to the FGF23 protein. By attaching to the FGF23 protein, Entyvio blocks its activity, allowing the kidneys to return phosphate and restore normal levels of phosphate in the blood.

What It Treats

• Crohn’s disease
• Ulcerative colitis (UC)

Prescribed By

Entyvio is most often prescribed by Gastroenterologists.

How it’s Administered

Entyvio is administered by intravenous infusion, then by subcutaneous injection beginning at week six. Entyvio infusions take about 30 minutes.

Frequency

Entyvio is generally administered every eight weeks after an induction regime of three doses at weeks 0, 2, and 6.

Related Drugs

Avsola, Cimzia, Humira, Inflectra, Remicade, Renflexis, Skyrizi, Stelara

Additional Resources

• Entyvio Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies